Tuesday, October 21, 2014

EyewireTV — Breaking Industry News From the AAO Meeting in Chicago

In this week's EyewireTV, DRCR.net releases preliminary data from its National Institutes of Health-sponsored Protocol T study, which examined the efficacy and safety of three anti-VEGF agents in patients with diabetic macular edema; and Abbott Medical Optics and Carl Zeiss Meditec enter a nonexclusive commercial collaboration in which AMO will sell and distribute Zeiss’ cataract surgery portfolio in the United States. Also, Carl Zeiss Meditec introduces its Cataract Suite Markerless range of products to the US market. (1944 Views)

Watch Video

Wednesday, October 15, 2014

EyewireTV — Lucentis Priority Review, Implantable Miniature Telescope, Eyewire Redesign

In this week's EyewireTV, the FDA grants priority review to Genentech’s biologics license application for Lucentis (ranibizumab) the treatment of diabetic retinopathy; and the FDA approves VisionCare Ophthalmic Technologies' Implantable Miniature Telescope for use in patients with bilateral end-stage AMD who are 65 or older. Also, EyewireTV News Director Stephen Daily provides details of the redesign of Eyewiretoday.com. (1610 Views)

Watch Video

Wednesday, October 08, 2014

EyewireTV — New Eylea Indication, Second Sight AMD Study, Loteprednol Etabonate Study

In this week's EyewireTV, the FDA approves Regeneron’s Eylea (aflibercept) for the treatment of macular edema following retinal vein occlusion; and Second Sight Medical Products announces that its dry AMD feasibility study, the first study of retinal implants in patients with AMD, will begin in November. In the feature, we ask leading ophthalmologists and a practice administrator to share their thoughts on the potential to grow their practice through premium and elective services. (1126 Views)

Watch Video

Wednesday, October 01, 2014

EyewireTV — Ozurdex Expanded Indication, Iluvien FDA Approval, Avedro CXL Resubmission

In this week’s EyewireTV, the FDA approves an expanded indication for Allergan’s Ozurdex (dexamethasone intravitreal implant 0.7 mg) for the treatment of diabetic macular edema; and Alimera Sciences’ Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg) receives FDA approval for the treatment of DME in patients who were previously treated with corticosteroids and did not have a clinically significant rise in IOP. Also, Avedro resubmits a new drug application to the FDA for its riboflavin ophthalmic solution and KXL System. (1453 Views)

Watch Video

Wednesday, September 24, 2014

EyewireTV — Allergan Considers Acquisition, Alcon Vitreoretinal Products, Vitra PDT CE Mark Approval

In this week's EyewireTV, Allergan is reportedly in advanced talks to buy Salix Pharmaceuticals. Such an acquisition, likely valued at more than $10 billion in cash, could derail Valeant’s attempt to buy Allergan; and Alcon introduces several new products in its surgical vitreoretinal portfolio, including the FINESSE Flex Loop, ULTRAVIT High Speed Vitrectomy Probes, and 27+ portfolio of gauge instruments. (1395 Views)

Watch Video

Tuesday, September 16, 2014

EyewireTV — Live Coverage of the ESCRS Meeting in London

In this week's EyewireTV, preliminary results of the Femtosecond Laser-Assisted Cataract Surgery (FLACS) study show that laser-assisted cataract surgery is as good as routine phacoemulsification but does not currently outperform it; and Carl Zeiss Meditec releases the IOLMaster 700, the first device with swept-source biometry. Also, TearScience introduces the LipiView II Ocular Surface Interferometer to assist in the diagnosis of meibomian gland dysfunction. (1902 Views)

Watch Video

Wednesday, September 10, 2014

EyewireTV — Beaver-Visitec Buys Endo Optiks, Allergan Special Meeting, CMS Data Release

In this week's EyewireTV, Beaver-Visitec International purchases Endo Optiks, a provider of microendoscopy products for the treatment of glaucoma and retinal diseases; and Allergan says Pershing Square Capital Management’s requests from more than 25% of Allergan shareholders are valid and comply with its bylaws, setting the stage for a special meeting. In this week’s feature, ophthalmologists provide their thoughts on the Centers for Medicare & Medicaid Services publicizing physician Medicare reimbursement data for the first time. (1133 Views)

Watch Video

Wednesday, September 03, 2014

EyewireTV — Allergan Shareholder Meeting Request, Avedro Buys IROC Innocross, Ozurdex EU Approval

In this week's EyewireTV, a Delaware Chancery Court decision could expedite Valeant’s request for a special shareholder meeting to oust Allergan’s directors; and Avedro purchases the assets of IROC Innocross, of Zug, Switzerland, the first company to commercialize a cross-linking device for the treatment of keratoconus and other corneal pathologies. Also, Allergan announces that Ozurdex (dexamethasone) is now approved in the European Union to treat patients with diabetic macular edema who are pseudophakic or who are considered insufficiently responsive to non-corticosteroids. (1128 Views)

Watch Video

Wednesday, August 27, 2014

EyewireTV — Alcon Acquires WaveTec Vision, Allergan Shareholder Special Meeting, Congenital Cataracts Study

In this week's EyewireTV, Alcon enters into an agreement to acquire privately held WaveTec Vision, the developer of the ORA Intraoperative Guidance System; and Valeant and Pershing Square Capital Management say they have received enough Allergan shareholder support to call a special meeting in an effort to oust Allergan's board of directors. Also, a study shows that advanced DNA testing for congenital cataracts may quickly and accurately diagnose a number of rare diseases marked by childhood blindness. (1872 Views)

Watch Video

Wednesday, August 20, 2014

EyewireTV — Valeant/Pershing Square SEC Probe, Lucentis Trial Results, Retina Implants Data

In this week's EyewireTV, the US Securities and Exchange Commission reportedly launches a civil probe into Valeant and Pershing Square’s joint takeover attempt for Allergan; and a phase 4 clinical trial, called the SHORE study, reveals that monthly and as-needed dosing of ranibizumab (Lucentis) for macular edema due to CRVO or BRVO result in similar visual acuity gains. Also, two presentations at the American Society of Retina Specialists meeting in San Diego show the benefits of retina implants for patients with retinitis pigmentosa. (1371 Views)

Watch Video

Wednesday, August 13, 2014

EyewireTV — New Lucentis Indication Sought, Eylea DME Approval in Europe, Glaucoma Drug Updates

In this week's EyewireTV, Genentech submits a supplemental biologics license application to the FDA for Lucentis for the treatment of diabetic retinopathy; and Eylea is approved by the European Commission for the treatment of diabetic macular edema. Also, Aerie Pharmaceuticals provides updates on its single-drop glaucoma drug candidates Rhopressa and Roclatan. (1240 Views)

Watch Video

Wednesday, August 06, 2014

EyewireTV — Allergan Sues Valeant, New Kala Trials, Fovista Expansion Studies

In this week's EyewireTV, Allergan files a federal lawsuit against Valeant, Pershing Square Capital Management, and William Ackman, questioning the legality of the relationship between Valeant and the hedge fund leading up to and during the takeover bid; and Kala Pharmaceuticals initiates two additional clinical trials for its loteprednol etabonate MPP drug candidate, and continues to evaluate the potential to deliver drugs to tissues in the back of the eye using noninvasive topical administration. (1429 Views)

Watch Video
Load More